The biology of human lymphoid malignancies revealed by gene expression profiling.

Gene expression profiling provides a quantitative molecular framework for the study of human lymphomas. This genomic technology has revealed that existing diagnostic categories are comprised of multiple molecularly and clinically distinct diseases. Diffuse large B-cell lymphoma (DLBCL), for example, consists of three gene expression subgroups, termed germinal center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL, and primary mediastinal B-cell lymphoma (PMBL). These DLBCL subgroups arise from different stages of normal B-cell differentiation, utilize distinct oncogenic mechanisms, and differ in their ability to be cured by chemotherapy. Key regulatory factors and their target genes are differentially expressed among these subgroups, including BCL-6, Blimp-1, and XBP1. ABC DLBCL and PMBL depend upon constitutive activation of the NF-kappaB pathway for their survival but GCB DLBCL does not, demonstrating that this pathway is a potential therapeutic target for certain DLBCL subgroups. In DLBCL, mantle cell lymphoma, and follicular lymphoma, gene expression profiling has also been used to create gene expression-based models of survival, which have identified the biological characteristics of the tumors that influence their clinical behavior. In mantle cell lymphoma, the length of survival following diagnosis is primarily influenced by the tumor proliferation rate, which can be quantitatively measured by a proliferation gene expression "signature." Based on this accurate measure, the proliferation rate can now be viewed as an integration of several oncogenic lesions that each increase progression from the G1 to the S phase of the cell cycle. In DLBCL and follicular lymphoma, gene expression profiling has revealed that the molecular characteristics of non-malignant tumor-infiltrating immune cells have a major influence on the length of survival. The implications of these insights for the diagnosis and treatment of non-Hodgkin lymphomas are discussed.

[1]  L. Staudt,et al.  Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. , 2004, The New England journal of medicine.

[2]  P. Möller,et al.  Isotype-switched immunoglobulin genes with a high load of somatic hypermutation and lack of ongoing mutational activity are prevalent in mediastinal B-cell lymphoma. , 2001, Blood.

[3]  R. Hay,et al.  Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IκBα , 1999, Oncogene.

[4]  T. Hamblin,et al.  Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma. , 2002, Blood.

[5]  S. Horvath,et al.  Prostate Stem Cell Antigen Is Overexpressed in Prostate Cancer Metastases , 2005, Clinical Cancer Research.

[6]  L. Staudt,et al.  Small molecule inhibitors of IκB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling , 2005 .

[7]  H Stein,et al.  A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. , 2000, Blood.

[8]  R. Hay,et al.  Defective IκBα in Hodgkin cell lines with constitutively active NF-κB , 1998, Oncogene.

[9]  K. Offit,et al.  BCL-6 protein is expressed in germinal-center B cells. , 1995, Blood.

[10]  K. Calame,et al.  Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. , 2003, Immunity.

[11]  R. McKay,et al.  A nucleolar mechanism controlling cell proliferation in stem cells and cancer cells. , 2002, Genes & development.

[12]  R. Dalla‐Favera,et al.  Antigen receptor signaling induces MAP kinase-mediated phosphorylation and degradation of the BCL-6 transcription factor. , 1998, Genes & development.

[13]  A. Gartel,et al.  Myc-ARF (Alternate Reading Frame) Interaction Inhibits the Functions of Myc* , 2004, Journal of Biological Chemistry.

[14]  L. Staudt,et al.  Transcriptional repression by the proto-oncogene BCL-6. , 1996, Oncogene.

[15]  L. Staudt,et al.  Two newly characterized germinal center B-cell-associated genes, GCET1 and GCET2, have differential expression in normal and neoplastic B cells. , 2003, The American journal of pathology.

[16]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[17]  I Royston,et al.  IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. , 1997, Blood.

[18]  B. Dörken,et al.  Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. , 1997, The Journal of clinical investigation.

[19]  Y. Akao,et al.  Gene rearrangement and overexpression of PRAD1 in lymphoid malignancy with t(11;14)(q13;q32) translocation. , 1992, Oncogene.

[20]  Ash A. Alizadeh,et al.  The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. , 1999, Cold Spring Harbor symposia on quantitative biology.

[21]  Kuo-I Lin,et al.  Blimp-1-Dependent Repression of Pax-5 Is Required for Differentiation of B Cells to Immunoglobulin M-Secreting Plasma Cells , 2002, Molecular and Cellular Biology.

[22]  L. Staudt,et al.  Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. , 2004, Cancer cell.

[23]  L. Staudt,et al.  Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. , 2004, Blood.

[24]  L. Gordon,et al.  Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  P. Lichter,et al.  Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. , 1996, Blood.

[26]  L. Staudt,et al.  Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma , 2003, The Journal of experimental medicine.

[27]  E. Noordijk,et al.  Mantle-cell lymphoma: a population-based clinical study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  E. Schuuring,et al.  Cyclin D1 messenger RNA overexpression as a marker for mantle cell lymphoma. , 1995, Oncogene.

[29]  T. Curiel,et al.  Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity , 2003, Nature Medicine.

[30]  G. M. Wilson,et al.  Down-Regulation of Cyclin D1 Expression by Prostaglandin A2 Is Mediated by Enhanced Cyclin D1 mRNA Turnover , 2000, Molecular and Cellular Biology.

[31]  L. Staudt.  Molecular diagnosis of the hematologic cancers. , 2003, The New England journal of medicine.

[32]  M. Downes,et al.  The corepressor N-CoR and its variants RIP13a and RIP13Delta1 directly interact with the basal transcription factors TFIIB, TAFII32 and TAFII70. , 1998, Nucleic acids research.

[33]  A. Aderem,et al.  Molecular definition of distinct cytoskeletal structures involved in complement- and Fc receptor-mediated phagocytosis in macrophages , 1996, The Journal of experimental medicine.

[34]  Yau-Tsun Steven Li,et al.  Transcription factor B cell lineage-specific activator protein regulates the gene for human X-box binding protein 1 , 1996, The Journal of experimental medicine.

[35]  Adrian Wiestner,et al.  A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[36]  David Levens,et al.  Disentangling the MYC web , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[37]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[38]  E. Clark,et al.  Macrophage- and dendritic cell--dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF. , 2003, Blood.

[39]  E. Campo,et al.  p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. , 1998, Blood.

[40]  S. Horning,et al.  Follicular lymphoma: have we made any progress? , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  K. Rajewsky,et al.  M17: a novel gene expressed in germinal centers. , 1994, International immunology.

[42]  Y. Niho,et al.  Effects of cell differentiation on the synthesis of the third and fourth component of complement (C3, C4) by the human monocytic cell line U937. , 1992, Immunology.

[43]  L. Gordon,et al.  Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  L. Staudt,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[45]  F. McCormick,et al.  The RB and p53 pathways in cancer. , 2002, Cancer cell.

[46]  S. Horning,et al.  The natural history of initially untreated low-grade non-Hodgkin's lymphomas. , 1984, The New England journal of medicine.

[47]  W. Hiddemann,et al.  Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma. , 1997, Cancer research.

[48]  C. Thompson,et al.  Bcl-x rather than Bcl-2 mediates CD40-dependent centrocyte survival in the germinal center. , 1996, Blood.

[49]  B. Dörken,et al.  High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. , 1996, Blood.

[50]  Liming Yang,et al.  Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. , 2002, Immunity.

[51]  L. Staudt,et al.  Decision making in the immune system: Lymphoid Malignancies: the dark side of B-cell differentiation , 2002, Nature Reviews Immunology.

[52]  R. Hertzberg,et al.  Molecular Cloning and Characterization of the Human Anaphylatoxin C3a Receptor* , 1996, The Journal of Biological Chemistry.

[53]  L. Staudt,et al.  Direct Repression of prdm1 by Bcl-6 Inhibits Plasmacytic Differentiation1 , 2004, The Journal of Immunology.

[54]  K. Calame,et al.  Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation. , 1997, Science.

[55]  S. Mori,et al.  BCL-6 gene product, a 92- to 98-kD nuclear phosphoprotein, is highly expressed in germinal center B cells and their neoplastic counterparts. , 1995, Blood.

[56]  W. Paul,et al.  Fig1, an interleukin 4-induced mouse B cell gene isolated by cDNA representational difference analysis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[57]  G. Freeman,et al.  PD-L2 is a second ligand for PD-1 and inhibits T cell activation , 2001, Nature Immunology.

[58]  F. Zindy,et al.  Differential effects of p19Arf and p16Ink4a loss on senescence of murine bone marrow-derived preB cells and macrophages , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[59]  L. Staudt,et al.  The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. , 2003, Cancer cell.

[60]  Ash A. Alizadeh,et al.  Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. , 2004, The New England journal of medicine.

[61]  D. Leprince,et al.  Multiple domains participate in distance-independent LAZ3/BCL6-mediated transcriptional repression. , 1996, Biochemical and biophysical research communications.

[62]  K. Calame,et al.  BLIMP-1 mediates extinction of major histocompatibility class II transactivator expression in plasma cells , 2000, Nature Immunology.

[63]  G. Zhu,et al.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion , 1999, Nature Medicine.

[64]  Andrea Califano,et al.  Transcriptional analysis of the B cell germinal center reaction , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[65]  P. Gaulard,et al.  Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins. , 2003, The American journal of pathology.

[66]  Chung-Che Chang,et al.  Immunohistochemical Expression Patterns of Germinal Center and Activation B-cell Markers Correlate With Prognosis in Diffuse Large B-cell Lymphoma , 2004, American Journal of Surgical Pathology.

[67]  Robert Tibshirani,et al.  HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma. , 2003, Blood.

[68]  L. Staudt,et al.  Control of inflammation, cytokine expression, and germinal center formation by BCL-6. , 1997, Science.

[69]  P. Marynen,et al.  Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. , 2000, Cancer research.

[70]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[71]  L. Staudt,et al.  XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. , 2004, Immunity.

[72]  A. López-Guillermo,et al.  INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene. , 2000, The American journal of pathology.

[73]  N. Harris,et al.  Diffuse Large B-Cell Lymphoma of Bone: An Analysis of Differentiation-Associated Antigens With Clinical Correlation , 2003, The American journal of surgical pathology.

[74]  Neal N. Iwakoshi,et al.  Plasma cell differentiation requires the transcription factor XBP-1 , 2001, Nature.

[75]  J. Licht,et al.  Critical Residues within the BTB Domain of PLZF and Bcl-6 Modulate Interaction with Corepressors , 2002, Molecular and Cellular Biology.

[76]  Kathryn A. O’Donnell,et al.  An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets , 2003, Genome Biology.

[77]  Michael S. Kuhns,et al.  CTLA-4: new insights into its biological function and use in tumor immunotherapy , 2002, Nature Immunology.

[78]  K. Basso,et al.  Molecular Pathogenesis of Non-Hodgkin's Lymphoma: the Role of Bcl-6 , 2003, Leukemia & lymphoma.

[79]  E. Jaffe,et al.  Non-Hodgkin's Lymphomas Arising in Patients Successfully Treated for Hodgkin's Disease: A Clinical, Histologic, and Immunophenotypic Study of 14 Cases , 1992, The American journal of surgical pathology.

[80]  C. Copie-Bergman,et al.  MAL Expression in Lymphoid Cells: Further Evidence for MAL as a Distinct Molecular Marker of Primary Mediastinal Large B-Cell Lymphomas , 2002, Modern Pathology.

[81]  M. Privalsky,et al.  Transcriptional Repression by the SMRT-mSin3 Corepressor: Multiple Interactions, Multiple Mechanisms, and a Potential Role for TFIIB , 1998, Molecular and Cellular Biology.

[82]  G. Salles,et al.  Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. , 2001, Blood.

[83]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[84]  L. Staudt,et al.  BCL-6 expression during B-cell activation. , 1996, Blood.

[85]  E. Campo,et al.  Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. , 1997, Blood.

[86]  John McGrath,et al.  Hodgkin’s Disease , 1933, JAMA.

[87]  S. Elledge,et al.  Cyclin D1 provides a link between development and oncogenesis in the retina and breast , 1995, Cell.

[88]  John M Sedivy,et al.  A Large Scale Genetic Analysis of c-Myc-regulated Gene Expression Patterns* 210 , 2003, The Journal of Biological Chemistry.

[89]  Human thymic B cells largely overexpress the VH4 Ig gene family. A possible role in the control of tolerance in situ , 1997 .

[90]  Craig W. Reynolds,et al.  Complete molecular remissions induced by patient-specific vaccination plus granulocyte–monocyte colony-stimulating factor against lymphoma , 1999, Nature Medicine.

[91]  G. Thorbecke,et al.  Requirement for reverse immune surveillance for the growth of germinal center-derived murine lymphomas. , 2000, Seminars in cancer biology.

[92]  K. Rajewsky,et al.  Diffuse large cell lymphomas are derived from mature B cells carrying V region genes with a high load of somatic mutation and evidence of selection for antibody expression , 1997, European journal of immunology.

[93]  G. Freeman,et al.  Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.

[94]  J. Banchereau,et al.  Human germinal center B cells express the apoptosis-inducing genes Fas, c-myc, P53, and Bax but not the survival gene bcl-2 , 1996, The Journal of experimental medicine.

[95]  Ash A. Alizadeh,et al.  The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. , 2002, Blood.

[96]  R. Gascoyne,et al.  Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. , 2001, Blood.

[97]  Lieping Chen,et al.  B7-H1 pathway and its role in the evasion of tumor immunity , 2003, Journal of Molecular Medicine.

[98]  S. Pileri,et al.  Prognostic significance of CD44 expression in diffuse large B cell lymphoma of activated and germinal centre B cell-like types: a tissue microarray analysis of 90 cases , 2003, Journal of clinical pathology.

[99]  yang-xin fu,et al.  B7DC/PDL2 Promotes Tumor Immunity by a PD-1–independent Mechanism , 2003, The Journal of experimental medicine.

[100]  Karen Leroy,et al.  Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. , 2004, Blood.

[101]  E. Jaffe,et al.  Composite lymphoma. A clinicopathologic analysis of nine patients with Hodgkin's disease and B-cell non-Hodgkin's lymphoma. , 1991, American journal of clinical pathology.

[102]  J. Monod,et al.  Teleonomic mechanisms in cellular metabolism, growth, and differentiation. , 1961, Cold Spring Harbor symposia on quantitative biology.

[103]  L. Staudt,et al.  BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. , 2000, Immunity.

[104]  K. Whaley,et al.  Complement biosynthesis by mononuclear phagocytes , 1993, Immunologic research.

[105]  Michael Hölzel,et al.  A role for c-Myc in the regulation of ribosomal RNA processing. , 2003, Nucleic acids research.

[106]  T. Grogan,et al.  Deficient tumor-infiltrating T-lymphocyte response in malignant lymphoma: relationship to HLA expression and host immunocompetence. , 1993, Leukemia.

[107]  L. Staudt,et al.  Analysis of gamma c-family cytokine target genes. Identification of dual-specificity phosphatase 5 (DUSP5) as a regulator of mitogen-activated protein kinase activity in interleukin-2 signaling. , 2003, The Journal of biological chemistry.

[108]  D. Czerwinski,et al.  Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. , 2002, Blood.

[109]  O. Melnyk,et al.  Characterization of a candidate bcl-1 gene , 1991, Molecular and cellular biology.

[110]  R. Warnke,et al.  Mutational Analysis of IgVH and BCL-6 Genes Suggests Thymic B-cells Origin of Mediastinal (Thymic) B-cell Lymphoma , 2004, Leukemia & lymphoma.

[111]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[112]  I. Lossos,et al.  Higher grade transformation of follicular lymphoma: phenotypic tumor progression associated with diverse genetic lesions. , 2003, Seminars in cancer biology.

[113]  R S Chaganti,et al.  BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[114]  D. Ransohoff.  Rules of evidence for cancer molecular-marker discovery and validation , 2004, Nature Reviews Cancer.

[115]  L. Hale,et al.  B cells in epithelial and perivascular compartments of human adult thymus. , 2001, Human pathology.

[116]  R. Levy,et al.  Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. , 1992, The New England journal of medicine.

[117]  P. Allavena,et al.  Differential Expression and Regulation of Toll-Like Receptors (TLR) in Human Leukocytes: Selective Expression of TLR3 in Dendritic Cells1 , 2000, The Journal of Immunology.

[118]  B. Klein,et al.  Rearrangement of CCND1 (BCL1/PRAD1) 3' untranslated region in mantle-cell lymphomas and t(11q13)-associated leukemias. , 1994, Blood.

[119]  L. Staudt,et al.  Molecular diagnosis of lymphoid malignancies by gene expression profiling. , 2002, Current opinion in hematology.

[120]  T. Golub,et al.  The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. , 2003, Blood.

[121]  S. Akira,et al.  The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5 , 2001, Nature.

[122]  S. Poppema,et al.  TARC, a CC Chemokine, Is Frequently Expressed in Classic Hodgkin's Lymphoma But Not in NLP Hodgkin's Lymphoma, T-Cell-Rich B-Cell Lymphoma, and Most Cases of Anaplastic Large Cell Lymphoma , 2001, The American journal of surgical pathology.

[123]  F. Zindy,et al.  Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[124]  Nan Li,et al.  Cloning and functional characterization of human septin 10, a novel member of septin family cloned from dendritic cells. , 2003, Biochemical and biophysical research communications.

[125]  B. Dörken,et al.  Molecular mechanisms of constitutive NF-κB/Rel activation in Hodgkin/Reed-Sternberg cells , 1999, Oncogene.

[126]  A. López-Guillermo,et al.  Mantle cell lymphoma , 1998, Seminars in hematology.

[127]  D. Leprince,et al.  Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[128]  Wei Gu,et al.  Acetylation inactivates the transcriptional repressor BCL6 , 2002, Nature Genetics.

[129]  R. Gascoyne,et al.  Mantle cell lymphoma: a clinicopathologic study of 80 cases. , 1997, Blood.

[130]  E. Verdin,et al.  BCoR, a novel corepressor involved in BCL-6 repression. , 2000, Genes & development.

[131]  P. Pandolfi,et al.  The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation , 1997, Nature Genetics.

[132]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.

[133]  E. Campo,et al.  BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. , 2001, Cancer research.

[134]  G. Cattoretti,et al.  Commitment of B Lymphocytes to a Plasma Cell Fate Is Associated with Blimp-1 Expression In Vivo1 , 2000, The Journal of Immunology.

[135]  C. Watts,et al.  Multistep Autoactivation of Asparaginyl Endopeptidase in Vitro and in Vivo* , 2003, Journal of Biological Chemistry.

[136]  Carlos S. Moreno,et al.  MTA3, a Mi-2/NuRD Complex Subunit, Regulates an Invasive Growth Pathway in Breast Cancer , 2003, Cell.

[137]  H. Döhner,et al.  Gain of chromosome arm 9p is characteristic of primary mediastinal b‐cell lymphoma (MBL): Comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line , 2001, Genes, chromosomes & cancer.

[138]  P. Isaacson,et al.  Large cell lymphoma of the mediastinum: a B‐cell tumour of probable thymic origin , 1986, Histopathology.

[139]  Y. Qi,et al.  p19ARF directly and differentially controls the functions of c-Myc independently of p53 , 2004, Nature.

[140]  V. Diehl,et al.  Production of a monoclonal antibody specific for Hodgkin and Sternberg–Reed cells of Hodgkin's disease and a subset of normal lymphoid cells , 1982, Nature.

[141]  Ash A. Alizadeh,et al.  Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[142]  K. Akashi,et al.  Mouse Development and Cell Proliferation in the Absence of D-Cyclins , 2004, Cell.

[143]  H. Stein,et al.  Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. , 1999, Blood.

[144]  L. Staudt,et al.  Signatures of the immune response. , 2001, Immunity.

[145]  S. Pileri,et al.  A specific monoclonal antibody (PG-B6) detects expression of the BCL-6 protein in germinal center B cells. , 1995, The American journal of pathology.

[146]  E. Campo,et al.  variants of mantle cell lymphoma (MCL): implications for pathogenesis Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic , 2013 .

[147]  E. Prossnitz,et al.  cDNA cloning of a novel G protein-coupled receptor with a large extracellular loop structure. , 1996, Biochimica et biophysica acta.

[148]  K. Franssila,et al.  Ki‐67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma , 2002, European journal of haematology.

[149]  Todd,et al.  Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.

[150]  Robert A. Weinberg,et al.  Metastasis genes: A progression puzzle , 2002, Nature.

[151]  G. Sonenshein,et al.  Maintenance of nuclear factor-kappa B/Rel and c-myc expression during CD40 ligand rescue of WEHI 231 early B cells from receptor-mediated apoptosis through modulation of I kappa B proteins. , 1996, Journal of immunology.

[152]  Ulrich Siebenlist,et al.  Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells , 2001, The Journal of experimental medicine.

[153]  D. Bahler,et al.  Clonal evolution of a follicular lymphoma: evidence for antigen selection. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[154]  N. Rosen,et al.  A truncated cyclin D1 gene encodes a stable mRNA in a human breast cancer cell line. , 1994, Oncogene.